Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical Inc
Newave Pharmaceutical Inc
MacroGenics
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Stanford University
National Institutes of Health Clinical Center (CC)
University of California, Davis
Xencor, Inc.
Astellas Pharma Inc
Stanford University
Aziende Chimiche Riunite Angelini Francesco S.p.A
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
Fore Biotherapeutics
Barbara Ann Karmanos Cancer Institute
National Institutes of Health Clinical Center (CC)
MedImmune LLC
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Massachusetts General Hospital
University of Louisville
Alliance for Clinical Trials in Oncology
Morphotek
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Indiana University
Indiana University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
Northwestern University
NYU Langone Health
Roswell Park Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Arizona